Published online Jul 27, 2025. doi: 10.4254/wjh.v17.i7.107213
Revised: April 13, 2025
Accepted: June 25, 2025
Published online: July 27, 2025
Processing time: 129 Days and 13.7 Hours
Klebsiella pneumoniae infections (KPIs), particularly carbapenem-resistant Klebsiella pneumoniae (CRKP), pose significant challenges in liver transplantation (LT) recipients, with high morbidity and mortality. Guo et al’s study highlights risk factors, such as elevated day-one alanine aminotransferase levels and prolonged catheterization, and identifies polymyxin B and ceftazidime/avibactam as effective treatments. However, limitations like the absence of pre-transplant colonization data and host-pathogen interaction insights highlight the need for enhanced strategies. Future directions should include routine CRKP colonization surveillance, immune and genomic profiling, and the development of novel therapeutics. By integrating these approaches, we can improve the prevention, diagnosis, and treatment of KPIs in LT patients.
Core Tip: Klebsiella pneumoniae infections are a major challenge in liver transplantation recipients, particularly due to carbapenem-resistant strains. Effective management requires addressing key risk factors, including pre-transplant colonization and immune dysregulation. Advanced diagnostics like genomic profiling and resistome analysis can enhance understanding of resistance and virulence mechanisms. Optimizing treatment regimens, such as polymyxin B and ceftazidime/avibactam, and developing novel therapeutics targeting specific resistance mechanisms are critical. Routine surveillance and international collaboration can further improve infection control strategies, ensuring better outcomes for this vulnerable population. Integrating microbiology, immunology, and pharmacology advances is essential for transforming liver transplantation infection care.